로딩 중…
지수 로딩 중…
Kolon TissueGene, Inc.
950160· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
US
US₩16,110-4.16%
2026-10-08
Financials
Valuation Metrics
Kolon TissueGene, Inc.'s Market Cap is ₩1.4T. At end of 2025 it was ₩6.8T. Ranked #270 of 2,419 in KR market (top 11%), #71 of 1,638 on KOSDAQ (top 4%), #29 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-10-08)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.37T KRW | KR#270/2,419 Sec#29/231 |
| Revenue | 4.94B KRW | KR—/2,419 Sec—/231 |
| Net Income | -185.78B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 513.26B KRW | KR—/2,419 Sec—/231 |
| Net Assets | 204.15B KRW | KR—/2,419 Sec—/231 |
| Employees | 58 | KR#1,983/2,419 Sec#175/231 |
| Value | ||
| P/B | 6.71x | KR#2,283/2,419 Sec#199/231 |
| P/S | 277.08x | KR#2,402/2,419 Sec#219/231 |
| FCF Yield | -1.86% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -91.00% | KR—/2,419 Sec—/231 |
| ROA | -36.20% | KR—/2,419 Sec—/231 |
| Op. Margin | -501.38% | KR—/2,419 Sec—/231 |
| Revenue Growth | -15.21% | KR—/2,419 Sec—/231 |
| Financial Health | ||
| Debt Ratio | 151.42% | KR—/2,419 Sec—/231 |
| Total Debt | 57.52B KRW | KR—/2,419 Sec—/231 |
| FCF | -25.49B KRW | KR—/2,419 Sec—/231 |
| Cash | 67.58B KRW | KR—/2,419 Sec—/231 |
| Current Ratio | 0.33x | KR—/2,419 Sec—/231 |
| Performance | ||
| 1Y Return | -65.58% | KR#2,276/2,419 Sec#217/231 |
| 1M Return | -7.78% | KR#1,978/2,419 Sec#188/231 |
| From 52W High | -89.19% | KR#2,403/2,419 Sec#231/231 |
| 1Y MDD | -91.59% | KR#2,405/2,419 Sec#231/231 |
| Trading | ||
| Volume | 383,722 shares | KR#305/2,419 Sec#29/231 |
| Trading Value | 6.22B KRW | KR#330/2,419 Sec#36/231 |
| Foreign Own. | 5.17% | KR—/2,419 Sec—/231 |
| Per Share | ||
| EPS | -2,186 KRW | KR—/2,419 Sec—/231 |
| BPS | 2,403 KRW | KR#1,984/2,419 Sec#159/231 |
Company Info
Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic primary cells with genetically engineered counterparts. Established by Kwan H. Lee on June 9, 1999, the enterprise maintains its corporate headquarters in Rockville, Maryland.